Back to Journals » Biologics: Targets and Therapy » Call For Papers

ESCI
SJR OA
CiteScore
Impact Factor

Biologics: Targets and Therapy

ISSN: 1177-5491


       

The following Article Collection/ Thematic Series is currently open for submissions:

Cancer Radiotherapeutic Targets for Enhanced Radiosensitization and/or Radioprotection Strategies

Dove Medical Press is pleased to invite you to the upcoming Article Collection “Cancer Radiotherapeutic Targets for Enhanced Radiosensitization and/or Radioprotection Strategies” led by Professor Shuyu Zhang, Professor Shun Lu, and Professor Wenling Tu in Biologics: Targets and Therapy.

Cancer radiotherapy, a cornerstone in cancer treatment, continually evolves to enhance its efficacy and minimize side effects. This Article Collection delves into the pivotal theme of "Cancer Radiotherapeutic Targets for Enhanced Radiosensitization and/or Radioprotection Strategies." Radiosensitization involves making cancer cells more susceptible to radiation, while radioprotection focuses on safeguarding surrounding healthy tissues. Understanding and manipulating these targets can revolutionize radiotherapy outcomes. From molecular pathways to novel therapeutic agents, this Collection explores the diverse strategies employed to augment the precision and safety of cancer radiotherapy.

The significance of identifying targets for radiosensitization and radioprotection lies in the potential to optimize cancer treatment outcomes. By deciphering the molecular and cellular intricacies underlying these processes, researchers can fine-tune radiotherapeutic approaches, maximizing effectiveness while minimizing collateral damage. This Collection aspires to contribute to the evolution of personalized and targeted cancer treatments, heralding a new era in which patients experience improved responses and reduced side effects.

We invite contributions spanning various subjects within cancer radiotherapy. Subtopics include the identification of novel molecular targets, exploration of emerging therapeutic agents, and advancements in technology facilitating precision treatments. Original research articles, reviews, and clinical studies are sought to create a mosaic of insights that align with the journal's commitment to disseminating impactful research in the broader field of oncology. This Collection aims to catalyze discussions and foster collaborations to drive further innovation in the realm of cancer radiotherapy.

Keywords

Cancer Radiotherapy, Radiosensitization, Radioprotection, Molecular Targets, Therapeutic Advancements

All manuscripts submitted to this Article Collection will undergo desk assessment and a full peer-review. Please review the journal scope and author submission instructions prior to submitting a manuscript.

The deadline for submitting manuscripts is 31st December 2024. Please note normal Article Processing Charges apply.

Please submit your manuscript on our website, quoting the promo code OZOEM to indicate that your submission is for consideration in this Article Collection.

Please contact Marya Baig at [email protected] with any queries and discount codes regarding this Article Collection.

View all papers in this article collection

Call For Papers

Editor-in-Chief: Professor Shein-Chung Chow


To see where Biologics: Targets & Therapy is indexed online view the Journal Metrics.

What is the advantage to you of publishing in Biologics: Targets & Therapy?

  • It is an open access journal which means that your paper is available to anyone in the world to download for free directly from the Dove Medical Press website.
  • Unlike many traditional journals  your paper will not be rejected due to lack of space. We are an electronic journal and there are no limits on the number or size of the papers we can publish. 
  • The time from submission to a decision being made on a paper can, in many journals, take some months and this is very frustrating for authors. Biologics: Targets & Therapy has a quicker turnaround time than this. Generally peer review is complete within 3-4 weeks and the editor’s decision within 2-14 days of this. It is therefore very rare to have to wait more than 6 weeks for first editorial decision.
  • Many authors have found that our peer reviewers’ comments substantially add to their final papers.

To recover our editorial and production costs, and continue to provide our content at no cost to readers, we charge authors or their institution an article publishing charge.

PubMed
Biologics: Targets & Therapy is indexed on PubMed Central (title abbreviation: Biologics). All published papers in this journal are submitted to PubMed for indexing straight away.

Become a Favored Author and receive real benefits
If you haven't already joined the Dove Medical Press Favored Author Program I would encourage you to do so.  Why? To receive real benefits like fast-tracking and a personal coordinator for your paper, as well as a discount on the publication processing fee. Click here to go through to the Favored Author signup page.

Yours sincerely
Professor Shein-Chung Chow
Editor-in-Chief
Biologics: Targets & Therapy

Email: Editor-in-Chief

Related journals you may also be interested in: